Sanofi MS Drug Takes Double Hit With FDA, Trial Setbacks

Sanofi’s experimental multiple sclerosis drug got hit with two setbacks on Monday: a regulatory delay in the US as well as a failure in a late-stage clinical trial.

The US Food and Drug Administration decision on the medicine, called tolebrutinib, to treat an advanced form of multiple sclerosis will likely be delayed, with further guidance from the regulator at the end of the first quarter, the French drugmaker said. The shares plunged as much as 6.4% in early Paris trading, the biggest decline in more than three months.